Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Selleslag

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Leukemia|February 20, 2004
Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemiasP Vandenberghe, I Wlodarska, L Michaux, et al.
Leukemia|August 30, 2002
Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factorsM Oosterveld, P Muus, S Suciu, et al.
Acta Clinica Belgica|August 18, 2012
Recommendations in the event of a suspected transfusion-related acute lung injury (TRALI)P Van der Linden, M Lambermont, A Dierick, et al.
Bone Marrow Transplantation|August 5, 2000
CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cellsG Hale, P Jacobs, L Wood, et al.
Leukemia|August 5, 2005
Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia GroupsS Amadori, S Suciu, R Stasi, et al.
Leukemia|May 17, 2003
The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921)M Oosterveld, S Suciu, G Verhoef, et al.
Blood|October 6, 2001
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDST de Witte, S Suciu, G Verhoef, et al.
Bone Marrow Transplantation|November 15, 2011
European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilizationK Hübel, M M Fresen, J F Apperley, et al.
Genes, Chromosomes & Cancer|August 5, 2000
MLL amplification in myeloid leukemias: A study of 14 cases with multiple copies of 11q23L Michaux, I Wlodarska, M Stul, et al.
Leukemia|January 28, 2005
A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemiasF Speleman, B Cauwelier, N Dastugue, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Leukemia|February 20, 2004
Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemiasP Vandenberghe, I Wlodarska, L Michaux, et al.
Leukemia|August 30, 2002
Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factorsM Oosterveld, P Muus, S Suciu, et al.
Acta Clinica Belgica|August 18, 2012
Recommendations in the event of a suspected transfusion-related acute lung injury (TRALI)P Van der Linden, M Lambermont, A Dierick, et al.
Bone Marrow Transplantation|August 5, 2000
CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cellsG Hale, P Jacobs, L Wood, et al.
Leukemia|August 5, 2005
Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia GroupsS Amadori, S Suciu, R Stasi, et al.
Leukemia|May 17, 2003
The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921)M Oosterveld, S Suciu, G Verhoef, et al.
Blood|October 6, 2001
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDST de Witte, S Suciu, G Verhoef, et al.
Bone Marrow Transplantation|November 15, 2011
European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilizationK Hübel, M M Fresen, J F Apperley, et al.
Genes, Chromosomes & Cancer|August 5, 2000
MLL amplification in myeloid leukemias: A study of 14 cases with multiple copies of 11q23L Michaux, I Wlodarska, M Stul, et al.
Leukemia|January 28, 2005
A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemiasF Speleman, B Cauwelier, N Dastugue, et al.
Pageof 5